Cargando…

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Therapy for multiple myeloma (MM) has dramatically changed in the past decade with introduction of new drugs, but it is not clear if the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two five-year periods by diagnosis, 2001–2005 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Shaji K., Dispenzieri, Angela, Lacy, Martha Q., Gertz, Morie A., Buadi, Francis K., Pandey, Shivlal, Kapoor, Prashant, Dingli, David, Hayman, Suzanne R., Leung, Nelson, Lust, John, McCurdy, Arleigh, Russell, Stephen J., Zeldenrust, Steven R., Kyle, Robert A., Rajkumar, S. Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000285/ https://www.ncbi.nlm.nih.gov/pubmed/24157580 http://dx.doi.org/10.1038/leu.2013.313

Ejemplares similares

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
por: Milani, Paolo, et al.
Publicado: (2016)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation
por: Hwa, Yi L., et al.
Publicado: (2016)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
por: Pang, Li, et al.
Publicado: (2021)

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation
por: Chakraborty, Rajshekhar, et al.
Publicado: (2017)

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
por: Gonsalves, W I, et al.
Publicado: (2015)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Visram, Alissa, et al.
Publicado: (2021)

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
por: Paquin, Ashley R., et al.
Publicado: (2018)

Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation
por: Sy-Go, Janina Paula T., et al.
Publicado: (2020)

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
por: Lakshman, Arjun, et al.
Publicado: (2018)

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma
por: Ravi, Praful, et al.
Publicado: (2018)

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
por: Visram, Alissa, et al.
Publicado: (2021)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

Natural history of multiple myeloma with de novo del(17p)
por: Lakshman, Arjun, et al.
Publicado: (2019)

P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment
por: Vaxman, Iuliana, et al.
Publicado: (2020)

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma
por: Tschautscher, Marcella A., et al.
Publicado: (2020)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
por: Abdallah, Nadine, et al.
Publicado: (2020)

Outcomes after biochemical or clinical progression in patients with multiple myeloma
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
por: Ho, Matthew, et al.
Publicado: (2021)

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
por: Binder, M, et al.
Publicado: (2016)

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
por: Charalampous, Charalampos, et al.
Publicado: (2023)

Conditional survival in multiple myeloma and impact of prognostic factors over time
por: Abdallah, Nadine H., et al.
Publicado: (2023)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
por: Schmidt, Walker M., et al.
Publicado: (2023)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
por: Goel, Utkarsh, et al.
Publicado: (2023)

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

Kidney Transplant Outcomes of Patients With Multiple Myeloma
por: Heybeli, Cihan, et al.
Publicado: (2022)

Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death
por: Warsame, R, et al.
Publicado: (2015)

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
por: Binder, M, et al.
Publicado: (2017)

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
por: Kumar, Shaji K., et al.
Publicado: (2018)

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
por: Warsame, Rahma, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ivka0khcfcei0ord3k3kmvc9k6